A Phase 2A, Open-Label Study Assessing Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Single-Dose Subcutaneous Anti- Spike(s) SARS-COV-2 Monoclonal Antibodies (Casirivimab and Imdevimab) in High-Risk Pediatric Subjects Under 12 Years of Age
Latest Information Update: 08 Mar 2023
At a glance
- Drugs Casirivimab/imdevimab (Primary)
- Indications COVID-19 respiratory infection
- Focus Pharmacokinetics
- Sponsors Regeneron Pharmaceuticals
- 26 Jul 2022 Status changed from completed to discontinued due to SARS-CoV-2 variants impacting susceptibility to study drug.
- 26 Jul 2022 Status changed from completed to discontinued due to SARS-CoV-2 variants impacting susceptibility to study drug.
- 29 Jun 2022 Status changed from active, no longer recruiting to completed.